Infliximab (Inflectra®) is a biosimilar, and the SMC advises that infliximab (Inflectra®) is accepted for use in line with the current SMC and Healthcare Improvement Scotland advice for the reference product infliximab (Remicade®).
NICE has recently clarified its position with regards to the evaluation of biosimilars. These products will usually be considered in the context of a Multiple Technology Appraisal in parallel with their reference products in the indication under consideration. In other circumstances, where it is considered a review of the evidence for a similar biological medicinal product is necessary, NICE will consider producing an ‘Evidence summary new medicine’. Evidence summaries do not make recommendations hence the decision regarding the choice of biosimilar or originator biologic for an individual patient rests with the responsible clinician in consultation with the patient.